Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Record caution: Renal endpoint needs clarification at exactly 15 mL/min; section 8.7 and the PK population use different inequality wording.
Check source scope before reading a dose
JOURNAVX - official renal boundary and measure recheck
Product / population
JOURNAVX - official renal boundary and measure recheck; selected renal passages, not a complete prescribing monograph.
Renal method
CKD-EPI eGFR adjusted for body surface area, mL/min in the PK paragraph. Exact 15 boundary not explicitly assigned in section 8.7.
Source revision
Prescribing information revised January 2026.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Exactly 15 is written differently in the dosing and PK sections
Section 8.7 uses below 15 for avoidance and above 15 for usual dosing; the PK analysis includes at least 15. Exactly 15 is therefore not consistently assigned across the selected sections.
What to reconcile: Seek exact-label clarification at this endpoint. Do not round, silently change an inequality, or apply indexed eGFR when the source uses a BSA-adjusted measure.
DailyMed / Vertex Pharmaceuticals Incorporated · JOURNAVX - official renal boundary and measure recheck; selected renal passages, not a complete prescribing monograph.
Renal method: CKD-EPI eGFR adjusted for body surface area, mL/min in the PK paragraph. Exact 15 boundary not explicitly assigned in section 8.7. Source date: Prescribing information revised January 2026. Retrieved: 2026-09-09
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The January 2026 prescribing information retains avoidance below eGFR 15 mL/min and a same-dose statement above 15. Its PK analysis includes values >=15 using CKD-EPI adjusted for body surface area. The exact value 15 is not explicitly assigned by the renal dosing paragraph, so this recheck does not fill that boundary. The wording occurs in the official label as well as the RX mirror. Preserve the absolute mL/min measure, the distinction between PK and dose instructions, and the unresolved boundary.
RDM53-official-suzetrigine-journavx-90f3d04d76-C1 · Source locator: Sections 8.7 and 12.3; label header and prescribing-information revision.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.